Pardes Biosciences shares are trading higher after MediPacific agreed to acquire the company for $2.02-$2.19/share in cash plus contingent value rights.
Portfolio Pulse from Benzinga Newsdesk
MediPacific has agreed to acquire Pardes Biosciences for $2.02-$2.19 per share in cash plus contingent value rights. This has led to a rise in Pardes Biosciences' share price.
July 17, 2023 | 11:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pardes Biosciences' shares are trading higher after the acquisition announcement by MediPacific.
The acquisition announcement by MediPacific has led to a positive sentiment among investors, causing a surge in Pardes Biosciences' share price. The acquisition price is higher than the current trading price, which is a positive signal for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100